ArticleJournal of general internal medicine2010
Primary care physicians' attitudes regarding race-based therapies.
Article in Journal of general internal medicine, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.
- Physicians' Perceptions of Race and Engagement in Race-Based Clinical Practice: a Mixed-Methods Systematic Review and Narrative Synthesis.Journal of general internal medicine · 2022Pooled it
- Antihypertensive Medication Category Prescriptions and Blood Pressure Control in African Surinamese and Ghanaian Migrants with Hypertension in Amsterdam, The Netherlands: The HELIUS Study.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2025Article
- Cardiologists' Perspectives on BiDil and the Use of Race in Drug Prescribing.Journal of racial and ethnic health disparities · 2022Article
- Colorblind Racial Ideology and Physician Use of Race in Medical Decision-Making.Journal of racial and ethnic health disparities · 2022Article
- Cardiologists' Perspectives on Race-Based Drug Labels and Prescribing Within the Context of Treating Heart Failure.Health equity · 2019Article
- Factors Related to Physician Clinical Decision-Making for African-American and Hispanic Patients: a Qualitative Meta-Synthesis.Journal of racial and ethnic health disparities · 2018Article
- Physicians' knowledge, beliefs, and use of race and human genetic variation: new measures and insights.BMC health services research · 2014Article
- BiDil in the Clinic: An Interdisciplinary Investigation of Physicians' Prescription Patterns of a Race-Based Therapy.AJOB empirical bioethics · 2014Article
- Physicians' anxiety due to uncertainty and use of race in medical decision making.Medical care · 2014Article
- What are our AIMs? Interdisciplinary Perspectives on the Use of Ancestry Estimation in Disease Research.AJOB primary research · 2012Article
- Is race medically relevant? A qualitative study of physicians' attitudes about the role of race in treatment decision-making.BMC health services research · 2011Article
- Patient reactions to personalized medicine vignettes: an experimental design.Genetics in medicine : official journal of the American College of Medical Genetics · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 7 institutions in 1 country.
Funding
Abstract
backgroundThere is little to no information on whether race should be considered in the exam room by those who care for and treat patients. How primary care physicians understand the relationship between genes, race and drugs has the potential to influence both individual care and racial and ethnic health disparities.
objectiveTo describe physicians' use of race-based therapies, with specific attention to the case of BiDil (isosorbide dinitrate/hydralazine), the first drug approved by the FDA for a race-specific indication, and angiotensin-converting enzyme (ace) inhibitors in their black and white patients.
designQualitative study involving 10 focus groups with 90 general internists.
participantsBlack and white general internists recruited from community and academic internal medicine practices participated in the focus groups.Of the participants 64% were less than 45 years of age, and 73% were male. APPROACH: The focus groups were transcribed verbatim, and the data were analyzed using template analysis.
resultsThere was a range of opinions relating to the practice of race-based therapies. Physicians who were supportive of race-based therapies cited several potential benefits including motivating patients to comply with medical therapy and promoting changes in health behaviors by creating the perception that the medication and therapies were tailored specifically for them. Physicians acknowledged that in clinical practice some medications vary in their effectiveness across different racial groups, with some physicians citing the example of ace inhibitors. However, physicians voiced concern that black patients who could benefit from ace inhibitors may not be receiving them. They were also wary that the category of race reflected meaningful differences on a genetic level. In the case of BiDil, physicians were vocal in their concern that commercial interests were the primary impetus behind its creation.
conclusionsPrimary care physicians' opinions regarding race-based therapy reveal a nuanced understanding of race-based therapies and a wariness of their use by physicians.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.